Close Menu

NEW YORK – Shares of Fulgent Genetics were up nearly 16 percent in Thursday morning trading, following an announcement that the firm had landed a contract to perform coronavirus testing for New York City's schools.

On Wednesday afternoon, Fulgent, based in Temple City, California, announced it has partnered with New York City Health and Hospitals, a public benefit corporation that operates the city's municipal healthcare system, to provide back-to-school COVID-19 testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.